Progress in treatment of relapsed/refractory peripheral T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2020.02.004
- VernacularTitle:复发难治性外周T细胞淋巴瘤治疗进展
- Author:
Linjun ZHAO
1
;
Yuqin SONG
;
Jun ZHU
Author Information
1. 北京大学国际医院淋巴瘤科 102206
- From:
Journal of Leukemia & Lymphoma
2020;29(2):83-86
- CountryChina
- Language:Chinese
-
Abstract:
The peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphoma. The overall prognosis is poor with high risk of relapse after the first-line treatment. The 61st American Society of Hematology (ASH) Annual Meeting has covered many treatment advances of PTCL, especially for relapsed/refractory patients. The main contents include histone deacetylase inhibitors (HDACi), farnesyl transferase (FT) inhibitors, dual inhibitors of SYK/JAK signaling pathway, PI3K inhibition agent, programmed death 1 (PD-1) monoclonal antibody, anti-CD38 monoclonal antibody, and EZH1/2 dual inhibitor. New protocols and drugs have brought hope for relapsed/refractory PTCL patients.
